# Amylyx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amylyx-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.amylyx.com
- Total disclosed funding: $169M
- Latest round: Series C (Jul 20, 2021)
- Investors on record: 15

## About

Based in Massachusetts, US, and founded in 2013 by co-founders Joshua Cohen and Justin Klee, Amylyx Pharmaceuticals, Inc. operates as a pharmaceutical company working on developing a novel therapeutic for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. In July 2021, the company raised USD 135 million in Series C funding led by Viking Global Investors with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, aMoon, Marshall Wace, Tybourne Capital Management, Verition Fund Management, and Falcon Edge, as well as existing investors Morningside Ventures, 683 Capital Management, Belinda Termeer and Polaris Founders Capital. 

Amylyx Pharmaceuticals offers an oral drug candidate AMX0035, a combination of taurursodiol and Buphenyl, two existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, used for the early treatment of patients suffering from Alzheimer's and other neuroinflammation diseases. The company conducted the CENTAUR trial of AMX0035 which was a randomized, double-blind, placebo-controlled Phase II clinical trial completed in late 2019.

Amylyx Pharmaceuticals plans to support the clinical development and potential launch of its candidate product AMX0035, for the treatment of ALS, and further research and development in other neurodegenerative diseases.

## Funding rounds

- Series C, Jul 20, 2021, $135M — Bain Capital, Marshall Wace, Viking Global Investors, Alpha Wave Global, Verition Fund Management, Rock Springs Capital, 683 Capital Management, Perceptive Advisors, aMoon, Morningside, Woodline Partners, Polaris Founders Capital, Tybourne Capital Management
- Series B, Jul 1, 2020, $30M — 5Y Capital
- Series A, Aug 22, 2016, $4M — 5Y Capital, SUNU Ventures

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- SUNU Ventures (https://capitalatlas.ai/funds/sunu-ventures) — Series A
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series C
- Verition Fund Management — Series C
- Rock Springs Capital — Series C
- 683 Capital Management — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- aMoon (https://capitalatlas.ai/funds/amoon) — Series C
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C
- Woodline Partners — Series C
- Polaris Founders Capital (https://capitalatlas.ai/funds/polaris-founders-capital) — Series C
- Tybourne Capital Management (https://capitalatlas.ai/funds/tybourne-capital-management) — Series C